Posted by admin on Jul 17th, 2022

Strs Ohio raised its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) by 9.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 114,000 shares of the medical instruments supplier’s stock after buying an additional 9,400 shares during the period. Strs Ohio owned about 0.28% of Harvard Bioscience worth $707,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of HBIO. AMH Equity Ltd bought a new position in shares of Harvard Bioscience during the fourth quarter worth approximately $5,640,000. B. Riley Asset Management LLC bought a new position in shares of Harvard Bioscience during the fourth quarter worth approximately $4,176,000. Meros Investment Management LP bought a new position in shares of Harvard Bioscience during the fourth quarter worth approximately $3,049,000. Allspring Global Investments Holdings LLC bought a new position in shares of Harvard Bioscience during the fourth quarter worth approximately $1,610,000. Finally, Monarch Partners Asset Management LLC increased its stake in shares of Harvard Bioscience by 49.4% during the fourth quarter. Monarch Partners Asset Management LLC now owns 493,202 shares of the medical instruments supplier’s stock worth $3,477,000 after purchasing an additional 163,119 shares during the period. Institutional investors own 72.75% of the company’s stock.

A number of equities analysts have recently weighed in on HBIO shares. StockNews.com started coverage on Harvard Bioscience in a research note on Thursday, March 31st. They set a “hold” rating on the stock. TheStreet downgraded Harvard Bioscience from a “c” rating to a “d+” rating in a research report on Monday, May 23rd.

In other Harvard Bioscience news, CEO James W. Green bought 30,000 shares of Harvard Bioscience stock in a transaction on Friday, May 6th. The shares were purchased at an average price of $3.78 per share, with a total value of $113,400.00. Following the acquisition, the chief executive officer now owns 2,309,955 shares in the company, valued at approximately $8,731,629.90. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Harvard Bioscience news, CEO James W. Green bought 10,000 shares of Harvard Bioscience stock in a transaction on Monday, May 9th. The shares were purchased at an average price of $3.40 per share, with a total value of $34,000.00. Following the acquisition, the chief executive officer now owns 2,319,955 shares in the company, valued at approximately $7,887,847. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO James W. Green bought 30,000 shares of Harvard Bioscience stock in a transaction on Friday, May 6th. The stock was acquired at an average cost of $3.78 per share, for a total transaction of $113,400.00. Following the acquisition, the chief executive officer now owns 2,309,955 shares in the company, valued at approximately $8,731,629.90. The disclosure for this purchase can be found here. Company insiders own 6.20% of the company’s stock.

Shares of NASDAQ:HBIO opened at $3.65 on Friday. The company has a market capitalization of $150.53 million, a P/E ratio of -22.81 and a beta of 1.78. Harvard Bioscience, Inc. has a 1 year low of $3.25 and a 1 year high of $8.75. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.18 and a quick ratio of 1.13. The business’s 50 day simple moving average is $3.72 and its 200 day simple moving average is $5.12.

Harvard Bioscience (NASDAQ:HBIO – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $28.78 million for the quarter, compared to analyst estimates of $29.10 million. Harvard Bioscience had a positive return on equity of 9.06% and a negative net margin of 5.38%. During the same period in the prior year, the company earned $0.03 EPS. On average, research analysts anticipate that Harvard Bioscience, Inc. will post 0.26 EPS for the current fiscal year.

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating).

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Ventoux CCM Acquisition Corp. (NASDAQ:VTAQW) Short Interest Update

Southwest Gas Holdings, Inc. (NYSE:SWX) Position Raised by Strs Ohio